110 related articles for article (PubMed ID: 28729178)
1. Elevated Cardiovascular Disease Risk in Patients With Chronic Myelogenous Leukemia Seen in Community-based Oncology Practices in the United States.
Coutinho AD; Makenbaeva D; Farrelly E; Landsman-Blumberg PB; Lenihan D
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):676-683. PubMed ID: 28729178
[TBL] [Abstract][Full Text] [Related]
2. Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines.
Jabbour E; Makenbaeva D; Lingohr-Smith M; Lin J
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):797-802. PubMed ID: 26603185
[TBL] [Abstract][Full Text] [Related]
3. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
[TBL] [Abstract][Full Text] [Related]
4. Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
Gunnarsson N; Sandin F; Höglund M; Stenke L; Björkholm M; Lambe M; Olsson-Strömberg U; Richter J; Själander A
Eur J Haematol; 2016 Oct; 97(4):387-92. PubMed ID: 26833713
[TBL] [Abstract][Full Text] [Related]
5. Framingham-Based Cardiovascular Risk Estimates Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study.
Lipton RB; Reed ML; Kurth T; Fanning KM; Buse DC
Headache; 2017 Nov; 57(10):1507-1521. PubMed ID: 28990165
[TBL] [Abstract][Full Text] [Related]
6. Risk and impact of tuberculosis in patients with chronic myeloid leukemia: a nationwide population-based study in Taiwan.
Liu CJ; Hong YC; Teng CJ; Hung MH; Hu YW; Ku FC; Chen YT; Chien SH; Yeh CM; Chen TJ; Chiou TJ; Gau JP; Tzeng CH
Int J Cancer; 2015 Apr; 136(8):1881-7. PubMed ID: 25208807
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
8. Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor.
Uemura M; Imataki O; Kawachi Y; Kawakami K; Hoshijima Y; Matsuoka A; Kadowaki N
Int J Hematol; 2016 Nov; 104(5):621-627. PubMed ID: 27492732
[TBL] [Abstract][Full Text] [Related]
9. Risk of Cardiovascular Disease Associated with a Restless Legs Syndrome Diagnosis in a Retrospective Cohort Study from Kaiser Permanente Northern California.
Van Den Eeden SK; Albers KB; Davidson JE; Kushida CA; Leimpeter AD; Nelson LM; Popat R; Tanner CM; Bibeau K; Quesenberry CP
Sleep; 2015 Jul; 38(7):1009-15. PubMed ID: 26083613
[TBL] [Abstract][Full Text] [Related]
10. Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century.
Pulte D; Redaniel MT; Bird J; Jeffreys M
Eur J Haematol; 2015 Jun; 94(6):540-5. PubMed ID: 25315799
[TBL] [Abstract][Full Text] [Related]
11. Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.
Gunnarsson N; Höglund M; Stenke L; Wållberg-Jonsson S; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Wadenvik H; Richter J; Själander A
Leukemia; 2016 Jul; 30(7):1562-7. PubMed ID: 27080811
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US).
Sharathkumar AA; Soucie JM; Trawinski B; Greist A; Shapiro AD
Haemophilia; 2011 Jul; 17(4):597-604. PubMed ID: 21323799
[TBL] [Abstract][Full Text] [Related]
13. Chronic myelogenous leukemia in eastern Pennsylvania: an assessment of registry reporting.
Mertz KJ; Buchanich JM; Washington TL; Irvin-Barnwell EA; Woytowitz DV; Smith RE
J Registry Manag; 2015; 42(1):9-11. PubMed ID: 25961786
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
[TBL] [Abstract][Full Text] [Related]
15. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.
Brunner AM; Campigotto F; Sadrzadeh H; Drapkin BJ; Chen YB; Neuberg DS; Fathi AT
Cancer; 2013 Jul; 119(14):2620-9. PubMed ID: 23625575
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of chronic myeloid leukaemia: an update.
Höglund M; Sandin F; Simonsson B
Ann Hematol; 2015 Apr; 94 Suppl 2():S241-7. PubMed ID: 25814090
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of cardiometabolic risk factors in women considered low risk by traditional risk assessment.
Pollin IS; Kral BG; Shattuck T; Sadler MD; Boyle JR; McKillop L; Campbell C; Ashen MD; Nasir K; Redberg RF; Brintzenhofeszoc K; Blumenthal RS; Michos ED
J Womens Health (Larchmt); 2008; 17(6):947-53. PubMed ID: 18582174
[TBL] [Abstract][Full Text] [Related]
18. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.
Mohammadi M; Cao Y; Glimelius I; Bottai M; Eloranta S; Smedby KE
BMC Cancer; 2015 Nov; 15():850. PubMed ID: 26537111
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of chronic myeloid leukaemia (CML).
Rohrbacher M; Hasford J
Best Pract Res Clin Haematol; 2009 Sep; 22(3):295-302. PubMed ID: 19959081
[TBL] [Abstract][Full Text] [Related]
20. The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: a global perspective.
Mendis S
Prog Cardiovasc Dis; 2010; 53(1):10-4. PubMed ID: 20620420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
